A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cancer vaccine-EBV (Primary)
- Indications Epstein-Barr virus infections; Nasopharyngeal cancer
- Focus Therapeutic Use
Most Recent Events
- 21 Jul 2021 Biomarkers information updated
- 21 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 09 Feb 2009 New trial record